Fulcrum Therapeutics, Inc. - Common Stock (FULC)

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.

Wondering what's happening in Monday's pre-market session? Find an overview in this article.

On Saturday, the company reported promising early outcomes from its Phase 1b PIONEER trial for sickle cell disease (SCD).

Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session. The market value of their outstanding shares is at $5.6 million.

In a financial landscape increasingly dominated by the towering valuations of large-cap technology giants, a quieter, yet potentially profound, narrative is unfolding within the small-cap segment of the stock market. Despite a prevailing cautious sentiment across broader markets, small-cap stocks are currently presenting an unusually attractive valuation proposition, trading at

After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

MyoKardia, a Bristol Myers unit, is terminating its agreement with Fulcrum Therapeutics, ending a cardiomyopathy research deal set to expire in June 2025.

The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.